Study of Unani Formulations in Asthma

Efficacy of Habb-e-Mubarak, Habb-e-Hindi Zeeqi and Montelukast in Zeeq-un-nafas â?? A Randomized Open Labelled Controlled Clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041190

Enrollment

120

Registered

2022-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Habb-e-Mubarak: 500 mg, two tablet x BD, orally with water for 45 days Control Intervention1: Habb-e-Hindi Zeeqi: 125 mg, two tablet x BD, orally with water for 45 days Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: •Known cases of mild to moderate Asthma •All gender •Age between 21 to 60 years •Non-smoker

Exclusion criteria

Exclusion criteria: •Known cases of Acute or severe Asthma (FEV1 (1) FEV1 (2) PEF variability 30% to at least 2 times during an 1-week monitoring period; (3) use of short-acting bronchodilating medication at least four times daily; and/or (4) Daily use of oral steroid •Subject with a History of COPD, Pneumonia, Occupational lung diseases and pulmonary tuberculosis •History of Smoking •Pregnant & lactating mothers

Design outcomes

Primary

Measure	Time frame
Improvement in Spirometry parametersTimepoint: On 0, 15,30, and 45th Day	—

Secondary

Measure	Time frame
Improvement in ACQTimepoint: On 0, 15,30, and 45th Day	—

Countries

India

Contacts

Public ContactKALEEM AHMAD

National Institute of Unani Medicine

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026